Results 21 to 30 of about 6,007,439 (376)

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database

Frontiers in Endocrinology, 2022
Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly improved clinical effects on glycemic control. However, real-world data concerning the difference in gastrointestinal adverse events (AEs) among different GLP-1 RAs are ...
Lu Liu, Jia Chen, Lei Wang, C. Chen, Li Chen   +4 more
semanticscholar   +1 more source

A Standardized Dataset of a Spontaneous Adverse Event Reporting System

Healthcare, 2022
One of the largest spontaneous adverse events reporting databases in the world is the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Unfortunately, researchers face many obstacles in analyzing data from the FAERS database. One
M. A. Khaleel, A. Khan, S. Ghadzi, A. Adnan, Qasem M A Abdallah   +4 more
semanticscholar   +1 more source

Trends in Adverse Event Rates in Hospitalized Patients, 2010-2019.

Journal of the American Medical Association (JAMA), 2022
Importance Patient safety is a US national priority, yet lacks a comprehensive assessment of progress over the past decade. Objective To determine the change in the rate of adverse events in hospitalized patients.
Noel E. Eldridge, Yun Wang, M. Metersky, Sheila Eckenrode, Jasie Mathew, N. Sonnenfeld, Jade K Perdue-Puli, David R. Hunt, P. J. Brady, Paul McGann, Erin N. Grace, David Rodrick, E. Drye, H. Krumholz   +13 more
semanticscholar   +1 more source

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system

Frontiers in Public Health, 2022
Background Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM) and chronic weight management in obesity or overweight adults. However, real-world data regarding its long-term gastrointestinal safety and tolerability in large sample ...
Yamin Shu, Xucheng He, Pan Wu, Yanxin Liu, Yufeng Ding, Qilin Zhang   +5 more
semanticscholar   +1 more source

Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States

JAMA Network Open, 2021
Key Points Question Does public sentiment of human papillomavirus (HPV) vaccine safety align with spontaneous HPV vaccine adverse event reporting data? Findings This cross-sectional analysis of the 2015 to 2018 National Immunization Survey indicates a 79.
K. Sonawane, Yueh-Yun Lin, Haluk Damgacioglu, Yenan Zhu, Maria E Fernandez, J. Montealegre, C. G. Cazaban, Ruosha Li, D. Lairson, Ying Lin, A. Giuliano, A. Deshmukh   +11 more
semanticscholar   +1 more source

Data mining techniques for detecting signals of adverse drug reaction of cardiac therapy drugs based on Jinan adverse event reporting system database: a retrospective study

BMJ Open, 2023
Objective Cardiac therapy drugs are widely used in the treatment of heart disease. However, the concern regarding adverse events (AEs) of cardiac therapy drugs have been rising. This study aimed to analyse cardiac therapy drug-related AEs using the Jinan
Jing Yang, Lei Zheng, Yuyao Guan, Lei Ji, Yingmei Qi, Mingzhu Zhang, Qiuhong Zhang   +6 more
doaj   +1 more source

Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient‐Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative

Pediatric Blood & Cancer, 2016
Bryce B. Reeve, Molly McFatrich, Laura C. Pinheiro, Meaghann S. Weaver, Lillian Sung, Janice S. Withycombe, Justin N. Baker, Jennifer W. Mack, Mia K. Waldron, Deborah Gibson, Deborah Tomlinson, David R. Freyer, Catriona Mowbray, Shana Jacobs, Diana Palma, Christa E. Martens, Stuart Gold, Kathryn D. Jackson, Pamela S. Hinds   +18 more
openalex   +2 more sources

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)

Cancers, 2020
Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukemia (CML), can be associated to cardiovascular (CV) adverse events (AEs).
S. Cirmi, Asmae El Abd, L. Létinier, M. Navarra, F. Salvo   +4 more
semanticscholar   +1 more source

Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System

Scientific Reports, 2020
Adverse event reports submitted to the US Food and Drug Administration (FDA) were analyzed to map the safety profile of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).
Jing Huang, Long Meng, Bing Yang*, Shusen Sun, Zhigang Luo, Hong Chen   +5 more
semanticscholar   +1 more source

A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib

Expert Opinion on Drug Safety, 2020
Background Baricitinib is approved for the treatment of rheumatoid arthritis (RA). The authors retrospectively investigated adverse events (AEs) by data-mining a self-reporting database to better understand toxicities, especially since it has been used ...
Ling Peng, Kui Xiao, S. Ottaviani, J. Stebbing, Ying-jie Wang   +4 more
semanticscholar   +1 more source